A novel anti-CD47 antibody with therapeutic potential for NK/T-cell lymphoma
NK/T-cell lymphoma (NKTCL) is a rare type of non-Hodgkin lymphoma (NHL). Although L-asparaginase-based chemotherapy has significantly improved survival in early-stage patients, the prognosis is poor in advanced and relapsed or refractory patients. CD47 is a promising target for cancer immunotherapy....
Saved in:
| Main Authors: | Liping Qin, Yajun Li, Ruolan Zeng, Yizi He, Xiaoyan Chen, Ling Xiao, Hui Zhou |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2408088 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma
by: Dan Zhu, et al.
Published: (2024-12-01) -
Immunotherapeutic Blockade of CD47 Increases Virus Neutralization Antibodies
by: Lamin B. Cham, et al.
Published: (2025-05-01) -
Beyond cancer: The potential application of CD47-based therapy in non-cancer diseases
by: Wei-Qing Deng, et al.
Published: (2025-02-01) -
Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy
by: Mithunah Krishnamoorthy, et al.
Published: (2025-02-01) -
Catechin suppresses HNSC via STXBP1 dependent inhibition of macrophage infiltration and CD47 mediated immune evasion
by: Ling Hao, et al.
Published: (2025-07-01)